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Abstract
• The goal of this scholarly project was to evaluate the efficacy of
pharmacogenomic testing (PGx) versus treatment as usual (TAU) in
the treatment of major depressive disorder (MDD). According to
Huang & Lin (2015), MDD is characterized by multiple signs and
symptoms consisting of mood, vegetative, cognitive, and even
psychotic behaviors that may cause substantial impairment in the
functioning and quality of life in an affected individual. This
literature review consisted of articles found in PubMed, Cochrane,
and PsychINFO which were extensively reviewed. Articles prior to
2008 were excluded due to the ever-changing landscape of PGx
testing. In this review, 18 articles and studies were analyzed. This
review found favorable outcomes when treatment was guided by PGx
versus TAU while examining response and remission rates. Although
data varied, cost effectiveness suggested some positive results with
PGx although further investigations are needed due to limitations and
lack of studies. Despite many favorable outcomes, more evidence of
the effectiveness of PGx is needed to make a concrete
recommendation that PGx guided treatment is superior to TAU.
Information in this review will help clinicians decide if this is an
appropriate option for the treatment of MDD. With continued
research and ongoing studies this biotechnology is becoming more
available to the mainstream.
• Terms and mesh headings: depression, major depressive disorder,
pharmacogenomics, pharmacogenetics, treatment as usual,
pharmacotherapy, medication, selective serotonin reuptake
inhibitors, antidepressant, psychiatry and Patient Health
Questionnaire (PHQ-9)

Introduction
• According to the Diagnostic and Statistical Manual of Mental
Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013),
“major depressive disorder (MDD) is characterized as a serious illness
that causes a person to feel deeply sad (or wholly absent of feeling) most
of the day, nearly every day, for at least two weeks” Depression is the
leading cause of disability in the United states with an average of 400
million disability days each year. According to Greenberg at al. (2015),
this is a much higher number than other mental and physical conditions.
• Pharmacogenomics is the study of how genes affect an individual’s
response to medications. Pharmacogenomic testing can be utilized to see
what medications may be the most effective for a patient with the least
amount of side effects. Though the utilization of PGx appears beneficial
in choosing a medication tailored to a patient’s specific genes, the
clinician should continue to keep age, lifestyle, side effects, cost, and
comorbid factors in mind while using pharmacogenomics. MDD
continues to be a significant health condition that impacts people
regardless or devoid of age, race, or gender. Comorbidities are often
associated with depression which can make appropriate management
difficult. The goal of the clinician is to treat these patients with the best
possible medication choice while mindful of side effects, cost, and
outcomes.
• This project focused on medication management rather than other
treatment modalities. Treatment as usual (TAU) with medication
management is usually based on practice guidelines and the clinicians
own experience with certain medications that they believe will help
control current symptoms. The purpose of this article is to evaluate
whether PGx demonstrates improved clinical outcomes compared to
TAU.

Applicability to Clinical
Practice

Statement of the Problem
• Treatment of depression remains a difficult issue in primary care as
well as psychiatric medicine. Many of these patients require multiple
medication trials prior to finding a drug that works to control their
symptoms without causing unfavorable side effects. This process may
cause prolonged suffering with depression as well as a decrease in
quality of life and productivity. The cost and time strain of attempting
multiple medications continues to be a burden on the patient as well
as the medical community.
• Studies on pharmacogenomic testing for MDD are needed to
demonstrate which medications may have higher efficacy and lower
cost for both the patient and health care community. Medications are
uniquely metabolized based on multiple genetic variants which
pharmacogenomic testing can help identify. One consideration to
remember while reviewing these finding is that many medications are
not able to be analyzed with metabolism and genetic variances at this
time, therefore only medications included in the pharmacogenomic
testing databases are explored.

• As we strive to make mental health topics less taboo, the treatment of
these diseases will surely increase. With new advances such as PGx,
guided treatment will continue to be evaluated and hopefully show
positive outcomes for those suffering from such conditions.
• Treatment of MDD can be quite challenging whether it be by
psychiatry or family medicine. Being able to review an individual’s
genetics and how they may react and/or metabolize a drug should
eliminate time and cost while improving the patient’s mental health.
Many of these studies show that utilizing PGx has shown greater
improvement in depression rating scores, less cost associated with
treatment, and improved quality of life.
• Exploring and testing the effects of BDNF, cortisol, inflammatory
markers, and Vitamin D levels have revealed some common links
between a person’s overall health and MDD. As PGx continues to
evolve it is likely that we will see more studies evaluating the
CYP450 system to better understand the metabolism of many of
these drugs. As some insurance companies are now covering some or
all costs of these tests, it is presumed that they will become more
readily available and providers will receive proper education on the
utilization of PGx.

Research Question
• In patients with MDD, are medications guided by pharmacogenomic
testing in the treatment of MDD more effective in achieving response
and remission of symptoms compared with TAU based on depression
assessment scales?
• In patients with MDD, does medication management guided by
pharmacogenomic testing improve cost effectiveness in the
management of disease compared to TAU?

Literature Review
Pathophysiology of Major Depressive Disorder
• The Diagnostic and Statistical Manual of Mental Disorder (5th ed.; DSM-5;
American Psychiatric Association, 2013) is widely used by clinicians and
researchers alike to classify specific mental disorders. According to the
DSM-V, major depressive disorder (MDD) is diagnosed by having five out
of the following nine symptoms. Depressed mood most of the day which
occurs nearly every day, diminished interest or pleasure in almost all
activities, significant weight loss categorized as 5% of body weight in a
month, insomnia or hypersomnia, psychomotor agitation or retardation,
fatigue or loss of energy, feelings of worthlessness or excessive
inappropriate guilt, diminished ability to think or concentrate, or recurrent
thoughts of death/suicide or suicide attempt. Five of these nine symptoms
must be present nearly every day, during a two-week time frame. These
symptoms need to cause significant stress with social and occupational
impairment. Also, these episodes may not be attributable to the physiologic
effects of a substance or another medical condition (American Psychiatric
Association, 2013).
Pharmacogenomic testing to aid in the treatment of MDD
• In the meta-analysis performed by Rosenblat, Lee, and McIntyre (2018),
the authors focused on response and remission rate of MDD based on TAU
and PGx guided treatment. The PGx group had a response rate of 50%
compared to the unguided group at 36%. The pooled relative risk (RR) for
treatment response comparing guided versus unguided treatment was 1.36
or a 95% confidence interval in favor of guided treatment and a (p=0.0006).
The pooled RR for remission was 1.74 or 95% confidence interval and a
(p=0.02) which demonstrates statistical significance. The remission rates of
the guided treatment group were 40% when compared to the unguided
group at 25%, respectively.

Cost Effectiveness of Pharmacogenomic Testing
• In a study by Benitez, Cool, and Scotti (2018), the authors evaluated
administrative claims by health plan members who were treated for
psychiatric conditions with PGx vs. TAU. These included prescriptions,
office visits, inpatient, and outpatient services. A major healthcare
insurance provider which consisted of over 25 million members was
used. Payments were evaluated for 24 months, pre and post treatment.
Although only records were reviewed, plan member records evaluated
had to be at least 18 years old and on a commonly prescribed
psychotropic medication starting within the past 180 days and without
other known history of psychotropic medication use. These could be
members who received TAU or PGx. Statistical significance was
evaluated by measuring the pre and post treatment cost controlling
demographics and comorbid conditions. They analyzed 205 members
treated by PGx and 478 with TAU. There was no significant difference in
the cohorts when age and gender were observed. Although over the
period studied the healthcare costs in both groups did rise, the TAU
increase was higher at $23,132 versus $17,627 (p=0.0004). The cost of
the PGx test was taken into consideration during these analyses. It was
noted that the reduced spending was mostly saved by a decrease in
outpatient services received.

Discussion
• Studies have shown some promise in the use of
pharmacogenomic testing for the treatment of MDD. MDD may
affect a person in many different aspects of their life whether it be
emotionally, physically, or financially. As the use of
pharmacogenomic testing in the treatment of MDD continues to
be explored, the very complicated disease process of MDD that
may stem from multiple variances in genes must be considered.
After reviewing the literature, the use of PGx may have a positive
impact in the treatment of MDD when compared to TAU. As
advances continue, this will help guide treatment and reduce the
cost associated with the treatment and management of MDD.
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